Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Trial of pIL-12 Electroporation Malignant Melanoma

ClinicalTrials.gov ID: NCT01502293

Public ClinicalTrials.gov record NCT01502293. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma

Study identification

NCT ID
NCT01502293
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
OncoSec Medical Incorporated
Industry
Enrollment
51 participants

Conditions and interventions

Conditions

Interventions

  • Tavokinogene Telseplasmid (tavo) Biological
  • OncoSec Medical System (OMS) Device

Biological · Device

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 13, 2012
Primary completion
Mar 20, 2016
Completion
Mar 20, 2016
Last update posted
May 14, 2023

2012 – 2016

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
UCSF Helen Diller Comprehensive Cancer Center San Francisco California 94115
John Wayne Cancer Institute Santa Monica California 90404
University of Colorado Denver Denver Colorado 80045
Lakeland Regional Cancer Center Lakeland Florida 33805
St. Luke's University Health Network Bethlehem Pennsylvania 18015
Seattle Cancer Care Alliance /University of Washington Cancer Consortium Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01502293, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 14, 2023 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01502293 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →